Synthetic Biologics Inc (SYN):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Synthetic Biologics Inc (SYN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7621
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:53
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Synthetic Biologics Inc (Synthetic Biologics), formerly Adeona Pharmaceuticals Inc is a clinical company that develops novel therapeutics to treat gut microbiome. The company’s pipeline products include SYN-004 and SYN-010. Its SYN-010 is a proprietary, modified-release formulation which is intended to treat rritable bowel syndrome with constipation. Synthetic Biologics’ SYN-004 is an oral prophylactic therapy for prevention of clostridium difficile infection, pathogenic overgrowth and the emergence of antimicrobial resistance. It develops preclinical monoclonal antibody therapies for the treatment of pertussis, and novel discovery stage biotherapeutics for the treatment of phenylketonuria. The company undertakes various research activities to develop therapeutics. It collaborates with various academic and pharmaceutical companies to develop its product candidates. Synthetic Biologics is headquartered in Rockville, Maryland, the US.

Synthetic Biologics Inc (SYN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Synthetic Biologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Synthetic Biologics Completes Acquisition Of C. difficile Infectious Disease Program Of Prev AbR 13
Venture Financing 15
SeeChange Health Raises US$3 Million In Venture Financing 15
Partnerships 16
Synthetic Biologics Enters into Research Agreement with Centers for Disease Control and Prevention 16
Intrexon Enters into Partnership with Synthetic Biologics 17
Synthetic Biologics and Enterome Bioscience Enter into Research Agreement 18
Synthetic Biologics Exapnds its Agreement With Intrexon To Develop Monoclonal Antibodies For Infectious Diseases 19
Licensing Agreements 20
Synthetic Biologics Enters Into Licensing Agreement With Cedars-Sinai Medical Center 20
Equity Offering 22
Synthetic Biologics Plans to Raise up to USD200 Million in Public Offering of Shares 22
Synthetic Biologics Raises USD12 Million in Private Placement of Series A Preferred Shares 23
Synthetic Biologics Raises USD25 Million in Public Offering of Common Stock and Warrants 24
Synthetic Biologics Raises USD46 Million in Public Offering of Shares 26
Synthetic Biologics Raises USD20.7 Million in Private Placement of Units 28
Synthetic Biologics Completes Public Offering Of Shares For US$13.2 Million 30
Synthetic Biologics Completes Private Placement Of Common Stock For US$11 Million 31
Acquisition 32
Hartlab Acquires Adeona Clinical Lab From Synthetic Biologics 32
Synthetic Biologics Inc – Key Competitors 33
Synthetic Biologics Inc – Key Employees 34
Synthetic Biologics Inc – Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Recent Developments 36
Financial Announcements 36
Aug 08, 2018: Synthetic Biologics reports second quarter 2018 operational highlights and financial results 36
May 08, 2018: Synthetic Biologics Reports First Quarter 2018 Operational Highlights And Financial Results 37
Feb 22, 2018: Synthetic Biologics Reports 2017 Year End Operational Highlights and Financial Results 39
Nov 01, 2017: Synthetic Biologics Reports Third Quarter 2017 Operational Highlights and Financial Results 40
Aug 03, 2017: Synthetic Biologics Reports Second Quarter 2017 Operational Highlights and Financial Results 41
May 04, 2017: Synthetic Biologics Reports First Quarter 2017 Operational Highlights and Financial Results 43
Mar 02, 2017: Synthetic Biologics Reports 2016 Year End Operational Highlights and Financial Results 45
Corporate Communications 47
May 22, 2018: Synthetic Biologics Announces Acceptance of Compliance Plan by NYSE American 47
Mar 07, 2018: Synthetic Biologics Reports on NYSE American Noncompliance Notice and Compliance Plan 48
Dec 05, 2017: Synthetic Biologics Announces Management Changes 49
Product News 50
01/18/2017: Synthetic Biologics Confirms Key Features of Pivotal Phase 2b/3 Trial of SYN-010 Pursuant to Consultations with FDA 50
Clinical Trials 51
Apr 19, 2017: Synthetic Biologics Reports Preclinical Data Demonstrating SYN-005 Provides Protection from Pertussis in Neonatal Animal Study 51
Appendix 53
Methodology 53
About GlobalData 53
Contact Us 53
Disclaimer 53

List of Tables
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Synthetic Biologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Synthetic Biologics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Synthetic Biologics Completes Acquisition Of C. difficile Infectious Disease Program Of Prev AbR 13
SeeChange Health Raises US$3 Million In Venture Financing 15
Synthetic Biologics Enters into Research Agreement with Centers for Disease Control and Prevention 16
Intrexon Enters into Partnership with Synthetic Biologics 17
Synthetic Biologics and Enterome Bioscience Enter into Research Agreement 18
Synthetic Biologics Exapnds its Agreement With Intrexon To Develop Monoclonal Antibodies For Infectious Diseases 19
Synthetic Biologics Enters Into Licensing Agreement With Cedars-Sinai Medical Center 20
Synthetic Biologics Plans to Raise up to USD200 Million in Public Offering of Shares 22
Synthetic Biologics Raises USD12 Million in Private Placement of Series A Preferred Shares 23
Synthetic Biologics Raises USD25 Million in Public Offering of Common Stock and Warrants 24
Synthetic Biologics Raises USD46 Million in Public Offering of Shares 26
Synthetic Biologics Raises USD20.7 Million in Private Placement of Units 28
Synthetic Biologics Completes Public Offering Of Shares For US$13.2 Million 30
Synthetic Biologics Completes Private Placement Of Common Stock For US$11 Million 31
Hartlab Acquires Adeona Clinical Lab From Synthetic Biologics 32
Synthetic Biologics Inc, Key Competitors 33
Synthetic Biologics Inc, Key Employees 34
Synthetic Biologics Inc, Subsidiaries 35

List of Figures
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Synthetic Biologics Inc (SYN):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Srei Infrastructure Finance Ltd
    Srei Infrastructure Finance Ltd - Strategy, SWOT and Corporate Finance Report Summary Srei Infrastructure Finance Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Vitasoy International Holdings Ltd.:企業の戦略・SWOT・財務分析
    Vitasoy International Holdings Ltd. - Strategy, SWOT and Corporate Finance Report Summary Vitasoy International Holdings Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Schiller AG:企業の戦略的SWOT分析
    Schiller AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Bayernoil Raffineriegesellschaft mbH:石油・ガス:M&Aディール及び事業提携情報
    Summary Bayernoil Raffineriegesellschaft mbH (Bayernoil) is an oil and gas company that offers refinery services to the oil and gas industry. The company provides products such as crude oil products, diesel, gasoline, fuel oil, bitumen, and others. It also offers liquefied fuels, heating oil, and sy …
  • Brooks MacDonald Group PLC (BRK):企業の財務・戦略的SWOT分析
    Brooks MacDonald Group PLC (BRK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Sparton Corporation:企業の戦略・SWOT・財務情報
    Sparton Corporation - Strategy, SWOT and Corporate Finance Report Summary Sparton Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Edgemont Pharmaceuticals LLC-製薬・医療分野:企業M&A・提携分析
    Summary Edgemont Pharmaceuticals LLC (Edgemont) is a pharmaceutical company that develops, acquires, and markets products for the treatment of psychiatric disorders. The company focuses on the development of novel drug formulations and therapies in the field of neuroscience. Its portfolio of product …
  • AngloGold Ashanti Ltd:企業の戦略・SWOT・財務情報
    AngloGold Ashanti Ltd - Strategy, SWOT and Corporate Finance Report Summary AngloGold Ashanti Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Vergnet SA (ALVER)-エネルギー分野:企業M&A・提携分析
    Summary Vergnet SA (Vergnet) is a renewable energy company. It designs, develops, and manufactures renewable solutions. The company offers wind, solar and hybrid energy solutions besides solar applications. Through its technology Hybrid Wizard, Vergnet offers real-time hybrid controller solutions fo …
  • British Airways Plc:企業の戦略・SWOT・財務情報
    British Airways Plc - Strategy, SWOT and Corporate Finance Report Summary British Airways Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Globe Telecom, Inc.:企業の戦略・SWOT・財務情報
    Globe Telecom, Inc. - Strategy, SWOT and Corporate Finance Report Summary Globe Telecom, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • SunTrust Wealth Management:企業の戦略・SWOT・財務情報
    SunTrust Wealth Management - Strategy, SWOT and Corporate Finance Report Summary SunTrust Wealth Management - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Genmedica Therapeutics SL-製薬・医療分野:企業M&A・提携分析
    Summary Genmedica Therapeutics SL (Genmedica) is a clinical-stage biopharmaceutical company that researches, discovers and develops orally available NCEs for the treatment of diabetes. The company’s expertise spans in the development of specific, dual-action, small molecule inhibitors that targets b …
  • Orig3N Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Orig3N Inc (Orig3N), a biotechnology company that focuses on the research, development and treatment of genetically inherited diseases. The company offers DNA test kits which include SUPERHERO for analyzing strength, intelligence and speed; FITNESS that provides reports and analysis on vario …
  • Rad Source Technologies Inc:企業の戦略的SWOT分析
    Rad Source Technologies Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Core-Mark Holding Company, Inc. (CORE):企業の財務・戦略的SWOT分析
    Core-Mark Holding Company, Inc. (CORE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Far East Hotels And Entertainment Limited:企業の戦略・SWOT・財務分析
    Far East Hotels And Entertainment Limited - Strategy, SWOT and Corporate Finance Report Summary Far East Hotels And Entertainment Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • Tobu Railway Co Ltd:企業の戦略・SWOT・財務情報
    Tobu Railway Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Tobu Railway Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Toshiba Corporation (6502):企業の財務・戦略的SWOT分析
    Toshiba Corporation (6502) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • SK Kaken Co Ltd (4628):企業の財務・戦略的SWOT分析
    SK Kaken Co Ltd (4628) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆